How much funding has OLIX raised?

OLIX has raised $213.0M in total funding, most recently a Series A round.

Who are OLIX's investors?

OLIX's investors include octopus investments, LocalGlobe, Entrepreneur First, Vertex Ventures.

Where is OLIX headquartered?

OLIX is headquartered in London, United Kingdom.

OLIX

Driving drug development through next-generation oligonucleotide technology

London, United Kingdom · Founded 2010 · $213.0M raised

Biotech

Headquarters: London
Employees: 51–200
Founded: 2010
Business Model: B2B

Website: olixpharma.com
Total Funding: $213.0M
Last Round: $213.0M Series AFeb 2026
Rounds: 1

About

OliX Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics using its proprietary cp-asiRNA and asiRNA platform technologies. The company is the first Asian organization to advance a self-developed RNAi technology into clinical trials, targeting dermal, ophthalmic, pulmonary, and hepatic diseases. Listed on KOSDAQ (226950), OliX is headquartered in Suwon, South Korea.

Summary

OLIX is a Biotech company based in London, United Kingdom, founded in 2010. It has raised $213.0M in total across 1 round, most recently a $213.0M Series A round in Feb 2026. Investors include octopus investments, LocalGlobe and Entrepreneur First.

LinkedIn X (Twitter)